Show simple item record

dc.contributor.advisorMeyer, Mervin
dc.contributor.advisorRees, Jasper
dc.contributor.authorKanyanda, Stonard Sofiel Elisa
dc.date.accessioned2015-02-10T11:34:28Z
dc.date.available2015-02-10T11:34:28Z
dc.date.issued2013
dc.identifier.urihttp://hdl.handle.net/11394/3960
dc.descriptionPhilosophiae Doctor - PhDen_US
dc.description.abstractCancer is one of the leading causes of death worldwide. According to the WHO, cancer accounted for 7.4 million deaths world wide in 2004. The metallo-compound cisplatin has been used for years as an effective antitumor agent for treating solid tumours such as breast, bladder, lung, oesophageal, and head and neck carcinomas. However, the use of cisplatin as an antitumor agent has been limited because of its association with problems such as lack of selectivity for cancer cells over normal cells, development of resistance to cisplatin treatment, and side effects such as nephrotoxicity. Recent studies on anticancer drugs have focussed on alternative anticancer agents such as gold compounds in both Au(I) and (III) oxidation states, which have shown to be potential anticancer drug agents because of their ability to induce apoptosis in several human cancer cells. Some gold complexes have shown to be able to selectively kill cancer cells over normal cells.en_US
dc.language.isoenen_US
dc.subjectAnti-cancer drugen_US
dc.subjectApoptosisen_US
dc.subjectCytotoxicityen_US
dc.subjectCytoprotectionen_US
dc.subjectGold(I) complexesen_US
dc.subjectThioredoxinen_US
dc.subjectLipid peroxidationen_US
dc.subjectOxidative damageen_US
dc.subjectPhosphine ligandsen_US
dc.subjectReactive oxygen speciesen_US
dc.titleDevelopment and characterization of pro-apoptotic drug candidates for anticancer drug discoveryen_US
dc.rights.holderUniversity of the Western Capeen_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record